Maravai LifeSciences (MRVI) Tops Q1 EPS by 4c

Maravai LifeSciences (NASDAQ: MRVI) reported Q1 EPS of $0.24, $0.04 better than the analyst estimate of $0.20. Revenue for the quarter came in at $148.2 million versus the consensus estimate of $138.49 million.

GUIDANCE:

Maravai LifeSciences sees FY2021 EPS of $1.04-$1.12, versus the consensus of $0.89. Maravai LifeSciences sees FY2021 revenue of $680-720 million, versus the consensus of $610.97 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
• Adobe (ADBE) PT Raised to $315 at RBC Capital
• National Health Investors (NHI) PT Lowered to $80 at Truist Securities